PRS7 THE CHRONIC OBSTRUCTIVE PULMONARY DISEASE HAS A NEGATIVE IMPACT ON THE QUALITY OF LIFE OF THE PATIENT: THE RESULTS OF THE EPIDEPOC STUDY  by García, M et al.
730 Abstracts
observational study was conducted prospectively in a parallel
group design. In 22 hospitals, 580 patients were enrolled, 261
patients in the moxiﬂoxacin-(M-)cohort and 319 patients in the
standard-(S-)cohort of other antibiotics. The economic perspec-
tive of a German hospital was applied for the cost measurement.
After conduct of the study, the patient data were grouped into
the relevant German DRG and the course of treatment, costs and
reimbursement of both cohorts were analysed. RESULTS: The
outcome of the patients at the beginning of treatment was com-
parable in both cohorts. The length-of-stay of the patients was
signiﬁcantly shorter in the moxiﬂoxacin cohort for the more
severe DRGs E62A (M-cohort 10.1 days, N = 113; S-cohort 12.2
days, N = 164; p = 0.004) and E62B (M-cohort 9.7 days, N =
112; S-cohort 10.7 days, N = 146; p = 0.041). In the third DRG
E62C no differences were found (M-cohort 10.2 days, N = 36;
S-cohort 9.4 days, N = 9; p = 0.306). Net proﬁt per case for the
hospitals in the DRG E62A was 1931€ and 1683€ for the cohorts
M and S respectively (E62B: M 1365€, S 1296€; E62C: M 802€,
S 791€). CONCLUSIONS: For the treatment of hospitalised
CAP the study demonstrated the economical relevance of fast
recovery secondary to efﬁcacious drug therapy. Under current
reimbursement modalities the treatment with moxiﬂoxacin is
more proﬁtable from the hospitals’ perspective due to a short-
ened length of stay of the patients.
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OBJECTIVES: Since the beginning of 2004, the diagnosis-related-
groups (DRG) are implemented in the reimbursement procedure
for German hospitals representing a signiﬁcant change for the
hospitals economic situation. As an example for non-invasive
treatment procedures in a German hospital, a prospective health
economic study evaluated the treatment costs of community-
acquired pneumonia (CAP) from the hospital’s perspective.
Results of an interim analysis were published in 2003, now the
ﬁnal results of the study are presented. METHODS: Open, non-
randomized prospective observational study from the perspective
of the German hospital administration. In 11 study centres, 319
patients were enrolled. A process-cost-analysis was performed to
determine the costs for the German hospital sector starting from
the admission up to the discharge of the patient. The cost calcu-
lation comprises diagnostic and therapeutic measures, drugs,
hotel costs and nursing. Both personnel costs and material costs
were included. Acquisition of medical devices was not included
into the analysis. RESULTS: The patients enrolled suffered from
moderate to severe stages of CAP with a mean length-of-stay of
11.5 days (peripheral ward: 10.7; ICU 0.8). Mean costs per
patient amounted to 1528€ (SD: 1011€). Most important cost-
driving factors were hotel costs (640€) and nursing (554€). Drug
acquisition cost resulted in 201€, whereas costs for diagnostics
(80€) and therapeutic measures (54€) were comparatively low.
The most often applied drugs were macrolides (37.6% of the
patients), b-lactamase inhibitor-aminopenicillin combinations
(32.3%), and cephalosporins of 2nd (30.4%) and 3rd generation
(28.5%). Thirty-six patients (11.3%) died during the hospital
stay. CONCLUSIONS: In hospitalised CAP, length of stay deter-
mines the costs from the economic perspective of the hospital,
which underlines the importance of a reduction of length of stay
in this indication. The need for rapid and safe antibiotic treat-
ment becomes evident especially under consideration of the DRG
reimbursement system.
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OBJECTIVE: To estimate health care costs for the treatment of
acute exacerbation of chronic bronchitis (AECB) and commu-
nity-acquired pneumonia (CAP) in 4 previously-reported Phase
III multinational comparative trials of telithromycin vs 
amoxicillin-clavulanic acid and clarithromycin in Canada.
METHODS: In each of the 4 studies, patients were followed for
1 month and the primary endpoint was clinical efﬁcacy at the
posttherapy/test of cure (TOC) visit. Each trial prospectively col-
lected data on study indication-related hospitalizations, addi-
tional health care provider visits, and additional antibiotic
therapy. Three trials also collected information on additional lab-
oratory and other tests and procedures. Cost analyses were per-
formed from the perspective of the Ontario Ministry of Health.
RESULTS: A total of 1045 and 853 patients in the 4 trials were
randomized to receive telithromycin or a comparator, respec-
tively. At baseline, the patient groups were similar with respect
to demographic and clinical characteristics. The clinical efﬁcacy
of telithromycin and the comparators was similar in each study.
Compared to patients randomized to comparator, those ran-
domized to telithromycin were less likely to require AECB- and
CAP-related hospitalization. Total and average costs of care were
approximately 2 to 3 times higher in the comparator groups,
driven by higher hospitalization rates. The ratio of average total
treatment cost per patient in each comparator to that of
telithromycin was as follows: $40/$19 = 2.1 for amoxicillin-
clavulanic acid in AECB; $241/$122 = 1.9 for clarithromycin in
AECB; $198/$109 = 1.8 and $293/$90 = 3.3, for clarithromycin
in CAP. CONCLUSION: Although clinical cure rates for
telithromycin, amoxicillin-clavulanic acid, and clarithromycin
are comparable, health care costs appear to be lower among
patients taking telithromycin, a ﬁnding driven by fewer hospi-
talizations. Since hospitalization accounts for a major propor-
tion of the direct health care costs associated with AECB and
CAP in Canada, the use of telithromycin may signiﬁcantly reduce
the total costs of care for these respiratory conditions.
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OBJECTIVES: COPD is a chronic disease that causes disability
and increases with age. The aim was to assess the quality of life
of COPD patient treated in Primary Assistance in Spain.
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METHODS: It is an epidemiological, observational, cross-
sectional and descriptive study. There were included mild or
severe COPD patients (according to FEV1 value). There were
collected demographic, clinical and comorbidity data. The
patients were asked to ﬁll the MOS SF-12 questionnaire.
RESULTS: A total of 10,711 patients were collected [75.6%
were male, 53.4% had moderate COPD (FEV1: 40–59%),
18.9% were active smokers and 21.8% were obese (CMI >/=
30)], with a mean age of 67.1 + 9.6 years and a COPD time evo-
lution period of 10.4 + 7.3 years. The 14.6% of the patients
answered that their health was bad and 55.4% could not make
the diary life activities because of their disease. Country nor-
malized physical (PCS) and mental health (MCS) component
summary scores (SF-12) indicated signiﬁcant impairment in both
domains compared to the general Spanish population: PCS; 36.0
+ 9.9 vs. 50.1 + 9.5, and MCS; 48.3 + 10.9 vs. 50.0 + 9.6, respec-
tively. PCS deteriorated independently with both age and sever-
ity of COPD, (p < 0.0001 in all cases), but no differences were
seen by smoking habit after adjusting by age, sex and severity.
PCS also deteriorated with number of hospitalizations and exac-
erbations (p < 0.0001), and in obese subjects (p < 0.0001). As
expected, MCS deteriorated slightly with age (p < 0.01), but no
differences were seen according to severity of disease. After
adjusting, non smoker and ex-smokers showed better MCS than
active smokers (p < 0.05). MCS also deteriorated with number
of hospitalizations and exacerbations (p < 0.001). CONCLU-
SIONS: COPD decreases patients’ physical and mental compo-
nents of QoL, while increasing level of disability in Spain. The
impairment in QoL increases with age, severity and exacerba-
tions of COPD.
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We examined the effects of expanded drug coverage, known as
the positive list, on the use and cost of medicines in three selected
areas of the Philippines. OBJECTIVES: To determine the impact
of the expanded drug coverage (positive list) on the drug uti-
lization, appropriateness and drug costs of managing pneumo-
nia, hypertension and other upper respiratory tract infections.
METHODS: A time series design consisting of 12 monthly time
points immediately before and after a 3-month implementation
period of the Positive List was used. A total of 24 hospitals were
randomly selected from major urban centers in the 3 main
islands of the country: National Capital Region (n = 12), Davao
(n = 6) and Cebu/Dumaguete (n = 6). The main outcome vari-
ables were changes in levels and trends from baseline in monthly
mean numbers of prescriptions per patient, monthly percentages
of antibiotic prescriptions, monthly average percentages of pre-
scriptions which were listed in the national formulary and Posi-
tive List, monthly mean appropriateness scores and monthly
total drug costs. RESULTS: A total of 8206 patient records from
24 hospitals were reviewed. Among patients with pneumonia,
the implementation of the Positive List was not signiﬁcantly asso-
ciated with changes in monthly mean number of prescriptions,
percentage of positive list drugs, percentage of generic prescrip-
tions, and mean cost of drugs per patient. Trends in appropri-
ateness scores were observed to remain steady before and after
the implementation of the expanded drug coverage. CONCLU-
SIONS: The implementation of the expanded drug coverage in
October 2000 had no effect on prescription rates, generic pre-
scription, and choice of antibiotic prescriptions. On the other
hand, the monthly percent prescriptions of drugs belonging in
the positive list was decreasing slowly before the policy and
increasing somewhat after.
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OBJECTIVES: We took into consideration clinical effectiveness,
costs and macroeconomic consequences of supplementation with
two slow release kalium compounds (Kalipoz prolongatum vs
Kaldyum) from payer (public insurer and patient) perspective.
METHODS: Results of a systematic review of clinical trials
referring to hypokaliemia treatment were used to assess effects
of kalium supplementation with Kalipoz or Kaldyum. DDD
(Deﬁned Daily Dose) costs for supplementation were calculated
from payer perspective (based on retailed prices of the drugs);
simulation was done to compare economic consequences per
therapy for payer in case of Kaldyum replacement by Kalipoz;
total annual sales of the drugs in Poland were taken into account
to assess macroeconomic consequences of kalium supplementa-
tion. RESULTS: Clinical effects of the compared drugs are
similar, adequate level of kalium in blood could be obtained with
both of the drugs. DDD for potassium chloride compounds is 3
g; cost of daily supplementation for payer is 1.36pln (0.3€) in
case of Kalipoz and 2.24pln (0.48€) or 2.5pln (0.54€) for
Kaldyum tablets (for 100 caps and 50 caps package respectively).
Supplementation for a period of a week with high dose (3g) of
Kalipoz is cheaper from payer perspective than with Kaldyum
100 caps and Kaldyum 50 caps (difference is 6.18pln (1.34€)
and 7.98pln (1.73€) respectively). Taking into consideration
macroeconomic consequences of potassium supplementation
savings for payer when use Kalipoz in place of Kaldyum could
be as high as 5.6mpln (1.2€m) per year. CONCLUSIONS:
Kalipoz prolongatum in place of Kaldyum supplementation 
signiﬁcantly reduce treatment costs for payer in treatment of
patients with hypokaliemia.
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OBJECTIVES: The HIV and HCV epidemics of the 1980’s and
1990’s highlighted the vulnerability of hemophilia patients to the
transmission of unknown blood-borne infections. Consequently,
the pharmaceutical industry has been charged with developing
recombinant concentrates with the least amount of human 
or animal proteins in order to reduce the chance of infection 
by emerging blood-borne infectious agents (e.g., viruses,
prions/nvCJD). In response, Antihemophilic Factor (recombi-
